Triodos Investment Management BV Has $2.42 Million Stock Holdings in OrthoPediatrics Corp. $KIDS

Triodos Investment Management BV grew its position in OrthoPediatrics Corp. (NASDAQ:KIDS) by 25.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 112,500 shares of the company’s stock after purchasing an additional 22,500 shares during the period. Triodos Investment Management BV owned about 0.46% of OrthoPediatrics worth $2,415,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Brown Advisory Inc. boosted its stake in shares of OrthoPediatrics by 6.2% in the 1st quarter. Brown Advisory Inc. now owns 1,628,747 shares of the company’s stock valued at $40,116,000 after purchasing an additional 94,719 shares in the last quarter. Vanguard Group Inc. lifted its position in OrthoPediatrics by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 937,969 shares of the company’s stock worth $23,102,000 after buying an additional 14,079 shares in the last quarter. Millennium Management LLC lifted its position in OrthoPediatrics by 55.3% during the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock worth $16,172,000 after buying an additional 233,873 shares in the last quarter. AWM Investment Company Inc. lifted its position in OrthoPediatrics by 5.5% during the 1st quarter. AWM Investment Company Inc. now owns 545,282 shares of the company’s stock worth $13,430,000 after buying an additional 28,488 shares in the last quarter. Finally, Harbor Capital Advisors Inc. lifted its position in OrthoPediatrics by 116.5% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 333,959 shares of the company’s stock worth $7,173,000 after buying an additional 179,733 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company’s stock.

Insider Activity at OrthoPediatrics

In related news, CFO Fred Hite purchased 5,076 shares of the stock in a transaction dated Thursday, August 21st. The stock was bought at an average cost of $19.41 per share, with a total value of $98,525.16. Following the purchase, the chief financial officer directly owned 213,065 shares in the company, valued at $4,135,591.65. The trade was a 2.44% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 32.70% of the stock is currently owned by company insiders.

OrthoPediatrics Stock Performance

Shares of KIDS stock opened at $17.95 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.66 and a quick ratio of 3.43. The stock has a market cap of $450.08 million, a PE ratio of -10.03 and a beta of 1.02. The stock has a 50-day moving average of $19.58 and a 200-day moving average of $21.10. OrthoPediatrics Corp. has a one year low of $16.59 and a one year high of $32.00.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Monday, January 9th. The company reported ($0.15) EPS for the quarter. The company had revenue of $25.08 million during the quarter. OrthoPediatrics had a negative net margin of 18.92% and a negative return on equity of 6.36%. As a group, sell-side analysts expect that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Analysts Set New Price Targets

KIDS has been the topic of several research reports. JMP Securities set a $35.00 price target on shares of OrthoPediatrics and gave the stock a “market outperform” rating in a research report on Friday, August 8th. Wall Street Zen upgraded shares of OrthoPediatrics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Wednesday. BTIG Research reduced their price target on shares of OrthoPediatrics from $40.00 to $39.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. Finally, Citigroup restated a “market outperform” rating on shares of OrthoPediatrics in a research report on Friday, August 8th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $34.14.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.